Beigene Ltd Share Price Hong Kong S.E.
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- HKD | - |
04-23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
04-23 | BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise | MT |
Sales 2024 * | 3.08B 24.14B 247B | Sales 2025 * | 3.92B 30.7B 314B | Capitalization | 16.05B 126B 1,285B |
---|---|---|---|---|---|
Net income 2024 * | -892M -6.98B -71.41B | Net income 2025 * | -356M -2.79B -28.5B | EV / Sales 2024 * | 4.72 x |
Net cash position 2024 * | 1.48B 11.6B 119B | Net cash position 2025 * | 1.13B 8.85B 90.52B | EV / Sales 2025 * | 3.8 x |
P/E ratio 2024 * |
-18
x | P/E ratio 2025 * |
-42.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.21% |
Latest transcript on Beigene Ltd
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
+3.21% | 13.68B | |
+33.54% | 12.17B | |
-24.71% | 8.24B |